6uyf

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:12, 6 November 2024) (edit) (undo)
 
(One intermediate revision not shown.)
Line 3: Line 3:
<StructureSection load='6uyf' size='340' side='right'caption='[[6uyf]], [[Resolution|resolution]] 2.06&Aring;' scene=''>
<StructureSection load='6uyf' size='340' side='right'caption='[[6uyf]], [[Resolution|resolution]] 2.06&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[6uyf]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Recombinant_hepatitis_c_virus_hk6a/jfh-1 Recombinant hepatitis c virus hk6a/jfh-1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UYF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6UYF FirstGlance]. <br>
+
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UYF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6UYF FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.06&#8491;</td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6uyf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uyf OCA], [http://pdbe.org/6uyf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6uyf RCSB], [http://www.ebi.ac.uk/pdbsum/6uyf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6uyf ProSAT]</span></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6uyf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uyf OCA], [https://pdbe.org/6uyf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6uyf RCSB], [https://www.ebi.ac.uk/pdbsum/6uyf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6uyf ProSAT]</span></td></tr>
</table>
</table>
-
<div style="background-color:#fffaf0;">
 
-
== Publication Abstract from PubMed ==
 
-
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry, with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell-based HCV vaccine development through E2 optimization and nanoparticle display. We redesigned variable region 2 in a truncated form (tVR2) on E2 cores derived from genotypes 1a and 6a, resulting in improved stability and antigenicity. Crystal structures of three optimized E2 cores with human cross-genotype NAbs (AR3s) revealed how the modified tVR2 stabilizes E2 without altering key neutralizing epitopes. We then displayed these E2 cores on 24- and 60-meric nanoparticles and achieved substantial yield and purity, as well as enhanced antigenicity. In mice, these nanoparticles elicited more effective NAb responses than soluble E2 cores. Next-generation sequencing (NGS) defined distinct B cell patterns associated with nanoparticle-induced antibody responses, which target the conserved neutralizing epitopes on E2 and cross-neutralize HCV genotypes.
 
-
Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines.,He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J Sci Adv. 2020 Apr 15;6(16):eaaz6225. doi: 10.1126/sciadv.aaz6225. eCollection, 2020 Apr. PMID:32494617<ref>PMID:32494617</ref>
+
==See Also==
-
 
+
*[[Antibody 3D structures|Antibody 3D structures]]
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 6uyf" style="background-color:#fffaf0;"></div>
+
-
== References ==
+
-
<references/>
+
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Human]]
 
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Recombinant hepatitis c virus hk6a/jfh-1]]
+
[[Category: Tzarum N]]
-
[[Category: Tzarum, N]]
+
[[Category: Wilson IA]]
-
[[Category: Wilson, I A]]
+
[[Category: Zhu J]]
-
[[Category: Zhu, J]]
+
-
[[Category: Bnab]]
+
-
[[Category: Broadly neutralizing antibody]]
+
-
[[Category: E2 core]]
+
-
[[Category: Hcv]]
+
-
[[Category: Self-assembly nanoparticle]]
+
-
[[Category: Vaccine design]]
+
-
[[Category: Viral proein-immune system complex]]
+
-
[[Category: Viral protein-immune system complex]]
+

Current revision

Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 6a bound to broadly neutralizing antibody AR3B

PDB ID 6uyf

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools